- 4D Molecular Therapeutics Inc 4D-150 Phase 2 PRISM Clinical Data Call TranscriptFeb 05, 2024
- 4D Molecular Therapeutics Inc 4D-710 Phase 1/2 AEROW Interim Clinical Data and Program Update Call TranscriptNov 01, 2023
- 4D Molecular Therapeutics Inc at Chardan Genetic Medicines Conference TranscriptOct 02, 2023
- 4D Molecular Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- 4D Molecular Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- 4D Molecular Therapeutics Inc 4D-710 Phase 1/2 AEROW Interim Clinical Data Call TranscriptJun 07, 2023
- 4D Molecular Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) TranscriptMay 30, 2023
- 4D Molecular Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- 4D Molecular Therapeutics Inc 4D-150 Phase 1/2 PRISM Interim Clinical Data - Corporate Call TranscriptApr 27, 2023
- 4D Molecular Therapeutics Inc 4D-310 Phase 1/2 Interim Clinical Data Call TranscriptFeb 22, 2023
- 4D Molecular Therapeutics Inc Phase 1/2 Clinical Trial of 4D-150 for Wet AMD - Corporate Call TranscriptNov 14, 2022
- 4D Molecular Therapeutics Inc Interim Clinical Data Presented at NACFC - Corporate Call TranscriptNov 03, 2022
- 4D Molecular Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- 4D Molecular Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- 4D Molecular Therapeutics Inc 4D-310 Phase 1/2 and 4D-110 Phase 1/2 Clinical Data Update Call TranscriptOct 25, 2021
4D Molecular Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) Transcript
Great. Good afternoon, everyone. Thanks for sticking with us for the last session of the day for our inaugural virtual genetic medicines day. Just a reminder, my name is Dae Gon Ha, one of the biotech analysts here at Stifel. (Conference Instructions)
But for now, the next 30 minutes, we're going to be discussing 4D Molecular. And from the company, we're going to be having both the CEO David Kirn; as well as a Chief Operating Officer and President, Fred Kamal.
So, David, I'll turn it over to you. David's got a couple of slides as an introductory remarks and then we'll dive into Q&A. So, David, thank you.
All right. Thanks for having us. Welcome, everyone. We'll just introduce the company through a few key slides upfront. So we're 4D Molecular Therapeutics, FDMT. This is our pipeline. We have a number of sustainable, large market gene therapy product opportunities in our portfolio.
We have products in ophthalmology, lung,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)